14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
RLMD vs CING: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Relmada Therapeutics, Inc. (RLMD) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RLMD carries a Unified Composite Score of 39.0/100 (SELL) at $3.00 (N/M Forward P/E, 0.0% operating margin), whereas CING carries 44.8/100 (HOLD) at $4.72 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. RLMD 39.0/100 SELL), RLMD captures the overall institutional head-to-head verdict (3–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: RLMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.2); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RLMD vs CING. Trailing 12-month operating profitability (RLMD 0.0% vs CING 0.0%) and valuation multiples (RLMD N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RLMD vs CING Key Questions & Quantitative Answers
As of Nov 17, 2026, Relmada Therapeutics, Inc. (RLMD) is the stronger overall head-to-head candidate over Cingulate Inc. (CING) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RLMD carries a Unified Composite Score of 39.0/100 (SELL) at $3.00 (N/M Forward P/E, 0.0% operating margin), whereas CING carries 44.8/100 (HOLD) at $4.72 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CING currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. RLMD 39.0/100 SELL), RLMD captures the overall institutional head-to-head verdict (3–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: RLMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.2); meanwhile CING is in a Breakdown options structure phase (RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RLMD leads the Growth & Scale pillar: RLMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CING at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RLMD generates N/A in USD-normalized revenue versus N/A for CING. In operating R&D and SG&A reinvestment, RLMD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CING.
RLMD and CING trade at balanced relative valuation multiples. RLMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLMD (-64.7% ROE) versus CING (-198.7% ROE) capital efficiency.
In options market volatility and institutional positioning, RLMD carries 93.2% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 107% Vol realized risk). By comparison, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.07β · 121% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.